SCHEMBL2394943

SCHEMBL2394943

COC(=O)c1ccc(C(=O)Nc2cc3c4c(c2)CCCC4CCC3)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.44
SMN1; SMN2 Q16637 7/20 0.44
NPC1 O15118 5/20 0.44
NFKB1 P19838 5/20 0.44
NFKB2 Q00653 5/20 0.44
RELA Q04206 5/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
POLB P06746 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
KDM4E B2RXH2 8/20 0.39
MAPT P10636 6/20 0.39
ALDH1A1 P00352 5/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2394784 0.89 NPC1 (0.47) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL2396701 0.81 ALDH1A1 (0.49) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL2396145 0.81 AR (0.42) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL2396265 0.80 SMN1; SMN2 (0.44) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL2393106 0.78 ALDH1A1 (0.48) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL2394759 0.76 MAPK1 (0.49) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL2396155 0.76 PTPN1 (0.51) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL2392565 0.75 MAPK1 (0.48) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL2394634 0.73 MAPK1 (0.48) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL2393644 0.72 NPC1 (0.50) RAB9ASMN1; SMN2NPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
EP-2189443-A1 TRICYCLIC AMIDE COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG RAB9A 1612/4885SMN1; SMN2 2048/4885NPC1 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.